October 21, 2021 -- Waters and the University of Delaware have initiated a five-year collaboration focused on improving quality, yields, and efficiency in the manufacturing processes for biologics and new modalities.
As part of the collaboration, Waters' staff and university researchers will co-locate at the Immerse Delaware Lab, a state-of-the-art lab located on the university's campus. The Immerse Delaware Lab will feature a purpose-built research test bed with a focus on leveraging Waters' liquid chromatography-mass spectrometry system, which was designed to simplify the multiattribute monitoring of biotherapeutics, Waters said.
Initial projects will seek to explore novel methods of quantifying and ultimately minimizing process-related impurities from uncontrolled glycosylation, which negatively impacts drug efficacy. The projects will be paired with informatic solutions to predict the evolution of biotherapeutic products, the company said.